Review article: New drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 7, 2008, Pages 815-829

  Ng, S C ^b   Kamm, M A ^a,c,d  

^a ST VINCENT S HOSPITAL   (Australia)

^b ST MARK S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BALSALAZIDE; BECLOMETASONE DIPROPIONATE; BETA INTERFERON; BETA1A INTERFERON; BUDESONIDE; BUDESONIDE MMX; CD3 ANTIBODY; CELLULOSE ACETATE; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; DIVISTYRAMINE; EPIDERMAL GROWTH FACTOR; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; MESALAZINE; METHYLPREDNISOLONE; MLN 02; NATALIZUMAB; OLSALAZINE; OMEGA 3 FATTY ACID; OPC 635; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; POLYESTER; PREDNISOLONE 3 SULFOBENZOATE; PREDOCOL; PROBIOTIC AGENT; ROSIGLITAZONE; SALAZOSULFAPYRIDINE; TACROLIMUS; TETOMILAST; TURMERIC; UNCLASSIFIED DRUG; VISILIZUMAB;

ARTHRALGIA; CHILL; CLINICAL TRIAL; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; ESCHERICHIA COLI; ESCHERICHIA COLI NISSLE 1917; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HUMAN; INJECTION SITE REACTION; INTESTINE FLORA; LEUKAPHERESIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELAPSE; REVIEW; SACCHAROMYCES BOULARDII; SURVIVAL RATE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; TRICHURIS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL FACTORS; COLITIS, ULCERATIVE; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; GASTROINTESTINAL AGENTS; HUMANS;

EID: 50849090911     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03800.x     Document Type: Review

References (121)

1. Stange EF, Travis SP. The European Consensus on ulcerative colitis: new horizons? Gut 2008 57: 1029 31.
2. Stange EF, Travis SPL, Geboes K, et al. European consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn's Colitis 2008 2: 1 23.
3. Travis SPL, Stange EF, Lemann M, et al. European consensus on the diagnosis and management of ulcerative colitis: current management. J Crohn's Colitis 2008 2: 24 62.
4. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2003 3: CD000543.
5. Sutherland L, Roth D, Beck P, et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2002 4: CD000544.
6. Myers B, Evans DNW, Rhodes J, et al. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 1987 28: 196 200.
7. Green JRB, Lobo AJ, Holdsworth CD, et al. Balsalazide is more effectivce and better tolerated than mesalamine in the treatment of acute ulcerative colitis. Gastroenterology 1998 114: 15 22.
8. Pruitt R, Hanson J, Safdi M, et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol 2002 97: 3078 86.
9. Hanauer SB. New lessons: classic treatments, expanding options in ulcerative colitis. Colorectal Dis 2006 8 (Suppl. 1 20 4.
10. Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001 96: 2929 33.
11. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003 114: 39 43.
12. Kamm MA, Sandborn W, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007 132: 66 75.
13. Lichtenstein GR, Kamm MA, Poddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007 5: 95 102.
14. TM mesalazine for maintenance of remission in ulcerative colitis. Gut 2008 57: 893 902.
15. Lichtenstein GR, Kamm MA, Karlstadt R, et al. MMX mesalamine is effective for the maintenance of ulcerative colitis remission in both left-sided and extensive disease. Am J Gastroenterol 2007 102: S462 [#936].
16. Sandborn WJ, Karlstadt R, Barrett K, et al. MMX mesalamine is effective for the maintenance of remission in mild-to-moderate ulcerative colitis irrespective of patients' relapse history. Am J Gastroenterol 2007 102: S461 [#935].
17. Kale-Pradhan PB, Pradhan RS, Wilhelm SM. Multi-matrix system mesalamine: to use or not to use. Ann Pharmacother 2008 42: 265 9.
18. McCormack PL, Robinson DM, Perry CM. Delayed-release multi matrix system (MMX) mesalazine: in ulcerative colitis. Drugs 2007 67: 2635 42.
19. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 1987 317: 1625 9.
20. Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis: a multicenter study. Ann Intern Med 1991 115: 350 5.
21. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005 100: 2478 85.
22. Sandborn WJ, Regula J, Feagan B, et al. Efficacy and safety of delayed-release oral mesalamine at 4.8 g/D (800 mg tablet) in the treatment of moderately active ulcerative colitis: results of the Ascend III study. Gastroenterology 2008 134 (Suppl. 1 102 [#702].
23. Brunner M, Greinwald R, Kletter K, et al. Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. Aliment Pharmacol Ther 2003 17: 1163 9.
24. Wilding IR, Kenyon CJ, Hooper G. Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa) dosed as either tablets or sachet. Aliment Pharmacol Ther 2000 14: 163 9.
25. Dignass A, Veerman H. Once- versus twice-daily mesalazine (pentasa) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomized controlled trial. Gut 2008 57: 002.
26. Farup PG, Hinterleitner TA, Lukas M, et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis 2001 7: 237 42.
27. Gandia P, Idier I, Houin G. Is once-daily mesalazine equivalent to the currently used twice-daily regimen? A study performed in 30 healthy volunteers. J Clin Pharmacol 2007 47: 334 42.
28. Raedler A, Behrens C, Bias P. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis - results from a randomized-controlled trial. Aliment Pharmacol Ther 2004 20: 1353 63.
29. Kruis W, Gorelov A, Kiudelis G, et al. Once daily dosing of 3 g mesalamine (Salofalk granules) is therapeutic equivalent to a three-times daily dosing of 1 g mesalamine for the treatment of active ulcerative colitis. Gastroenterology 2007 132: A-130 131.
30. Marteau P, Florent C. Comparative, open, randomized trial of the efficacy and tolerance of slow-release 5-ASA suppositories once daily versus conventional 5-ASA suppositories twice daily in the treatment of active cryptogenic proctitis. Am J Gastroenterol 2000 95: 166 70.
31. Marteau P, Crand J, Foucault J, et al. Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study. Gut 1998 42: 195 9.
32. D'Albasio G, Paoluzi P, Campieri M, et al. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group. Am J Gastroenterol 1998 93: 799 803.
33. Hanauer S, Good IL, Goodman MW, et al. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol 2000 95: 1749 54.
34. Yokoyama H, Takagi S, Kuriyama S, et al. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflamm Bowel Dis 2007 13: 1115 20.
35. Marshall JK, Irvine EJ. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995 9: 293 300.
36. Regueiro M, Loftus EV Jr., Steinhart AH, et al. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis 2006 12: 979 94.
37. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005 54: 960 5.
38. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumour necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology 1999 116: 602 9.
39. Sharon P, Ligumsky M, Rachmilewitz D, et al. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulphsalazine. Gastroenterology 1978 75: 638 40.
40. Allgayer H. Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther 2003 18: 10 4.
41. Desreumaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid-new evidence. Aliment Pharmacol Ther 2006 1 (Suppl. 1 2 9.
42. Dubuquoy L, Rousseaux C, Thuru X, et al. PPAR-γ as a new therapeutic target in inflammatory bowel disease. Gut 2006 55: 1341 9.
43. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal anti-inflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator- activated receptor-γ. J Exp Med 2005 201: 1205 15.
44. Lewis JD, Lichtenstein GR, Deren JJ, et al. Rosiglitazone for active ulcerative colitis: a randomized placebo controlled trial. Gastroenterology 2008 134: 688 95.
45. Liang HL, Ouyang Q. A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis. World J Gastroenterol 2008 14: 114 9.
46. Truelove SC. Systemic and local corticosteroids therapy in ulcerative colitis. Br Med J 1960 1: 464 7.
47. Rutgeerts P. Medical therapy of inflammatory bowel disease. Digestion 1998 59: 453 69.
48. Reshef R, Varkel J, Shiller M, et al. Systemic effects of rectally administered corticosteroid. Isr J Med Sci 1992 28: 98 100.
49. Harris DM. Some properties of beclomethasone dipropionate and related steroids in man. Postgrad Med J 1975 51 (Suppl. 4 20 5.
50. Steed KP, Hooper G, Ventura P, et al. The in vivo behavior of a colonic delivery system. Int J Pharm 1994 112: 199 206.
51. Campieri M, Adamo S, Valpiani D, et al. Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment Pharmacol Ther 2003 17: 1471 80.
52. Rizzello F, Gionchetti P, D'Arienzo A, et al. Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2002 16: 1109 16.
53. Biancone L, Gionchetti P, Blanco Gdel V, et al. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Dig Liver Dis 2007 39: 329 37.
54. Rhodes JM, Robinson R, Beales I, et al. Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis. Aliment Pharmacol Ther 2008 27: 228 40.
55. D'Haens GR, Kovacs A, Vergauwe P, et al. Safety and efficacy of a novel extended release budesonide formulation in patients with active left sided ulcerative colitis. Gastroenterology 2007 132 (Suppl. 2 T1276.
56. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005 353: 2462 76.
57. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Infliximab reduces colectomy in patients with moderate-to-severe-UC: colectomy analysis from ACT 1 and ACT 2. Gut 2007 56 (Suppl. III A26.
58. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006 3: CD005112.
59. Diez M, Sanchez E, Garcia Lopez S, et al. Infliximab therapy in ulcerative colitis: initial experience in two referral centers. Gastroenterol Hepatol 2007 30: 449 53.
60. D'Haens G, Daperno M. Advances in biologic therapy for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep 2006 8: 506 12.
61. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005 128: 1805 11.
62. Lees CW, Ho GT, Noble CL, et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Phamacol Ther 2007 26: 411 9.
63. Kohn A, Daperno M, Armuzzi A, et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long term follow-up. Aliment Phamacol Ther 2007 26: 747 56.
64. Jakobovits SL, Jewell DP, Travis PL. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment Pharmacol Ther 2007 25: 1055 60.
65. Peyrin-Biroulet L, Laclotte C, Roblin X, et al. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 2007 13: 2328 32.
66. Baumgart DC. The phase I/II visilizumab study. A report of safety and efficacy of treatment and retreatment in ulcerative colitis patients refractory to treatment with IV steroids. Gut 2005 54 (Suppl. VII A57.
67. Plevy S, Salzberg B, Van Assche G, et al. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 2007 133: 1414 22.
68. Lanzarotto F, Carpani M, Chaudhary R, et al. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin. Drugs 2006 66: 1179 89.
69. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005 353: 1912 25.
70. Gordon FH, Hamilton MI, Donoghue S, et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha 4 integrin. Aliment Pharmacol Ther 2002 16: 699 705.
71. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha 4 beta7 integrin. N Engl J Med 2005 352: 2499 507.
72. Van Assche G, Dalle I, Noman M, et al. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003 98: 369 76.
73. Van Assche G, Sandborn WJ, Feagan BG, et al. Daclizumab, a humanized monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomized, double blind, placebo controlled, dose ranging trial. Gut 2006 55: 1568 74.
74. Benson A, Barrett T, Sparberg M, et al. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis 2008 14: 7 12.
75. Ng SC, Arebi N, Kamm MA. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis 2007 13: 129 34.
76. Gonzalez-Lama Y, Gisbert JP, Mate J. The role of tacrolimus in inflammatory bowel disease: a systematic review. Dig Dis Sci 2006 51: 1833 40.
77. Chow DK, Leong RW. The use of tacrolimus in the treatment of inflammatory bowel disease. Expert Opin Drug Saf 2007 6: 479 85.
78. Ullman TA. Tacrolimus for active ulcerative colitis? Yes! (Even though Cochrane says "no") Gastroenterology 2007 132: 1192 4.
79. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994 330: 1841 5.
80. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001 120: 1323 9.
81. Shibolet O, Regushevskaya E, Brezis M, et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005 25: CD004277.
82. Moskovitz D, Van Assche G, Maenhout B, et al. Incidene of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006 4: 760 5.
83. Campbell S, Travis S, Jewell D. Cyclosporine use in acute ulcerative colitis: a long term experience. Eur J Gastroenterol Hepatol 2005 17: 79 84.
84. Actis GC, Fadda M, David E, et al. Colectomy rate in steroids-refractory colitis initially responsive to cyclosporine: a long-term restrospective cohort study. BMC Gastroenterol 2007 7: 13.
85. Shah SB, Parekh NK, Hanauer SB, et al. Intravenous cyclosporine in severe steroid-refractory ulcerative colitis: long term follow-up. Gastroenterology 2008 134 (Suppl. 1 133 [1041].
86. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus therapy in refractory ulcerative colitis. Gut 2006 55: 1255 62.
87. Herrlinger KR, Fellermann K, Stange EF. Tacrolimus-finally! Gut 2006 55: 1224 5.
88. Fellermann K, Tanko Z, Herrlinger KR, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002 8: 317 24.
89. Bamgaurt D, Wiedenmann B, Dignass AU, et al. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Alimen Pharmacol Ther 2003 17: 1273 81.
90. Sugimoto K, Hanai H, Tozawa K, et al. Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 2002 123: 1912 22.
91. Deguchi Y, Andoh A, Inatomi O, et al. Curcumin prevents the development of dextran sulfate sodium (DSS)-induced experimental colitis. Dig Dis Sci 2007 52: 2993 8.
92. Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006 4: 1502 6.
93. De Ley M, de Vos R, Hommes DW, et al. Fish oil for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007 4: CD005986.
94. Travis S, Yap LM, Hawkey C, et al. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm Bowel Dis 2005 11: 713 9.
95. Schreiber S, Keshavarzian A, Isaacs KL, et al. A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology 2007 132: 76 86.
96. Madsen SM, Schlichting P, Davidsen B, et al. An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left sided ulcerative colitis. Am J Gastroenterol 2001 96: 1807 15.
97. Sumer N, Palabiyikoglu M. Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis. Eur J Gastroenterol Hepatol 1995 7: 597 602.
98. Nikolaus S, Rutgeerts P, Fedorak R, et al. Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut 2003 52: 1286 90.
99. Sawada K, Kusugami K, Suzuki Y, et al. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol 2005 100: 1362 9.
100. Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997 11: 853 8.
101. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004 53: 1617 23.
102. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999 354: 635 9.
103. Dissanayake AS, Truelove SC. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin). Gut 1973 14: 923 6.
104. Bibiloni R, Fedorak RN, Tancock GW, et al. VSL#3 probiotic mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005 100: 1539 46.
105. Makharia GK, Sood A, Midha V, et al. A randomised, double blind, placebo-controlled trial of a probiotic preparation, VSL#3, for the treatment of mild to moderate active ulcerative colitis. Gastroenterology 2008 134: 102 [#701].
106. Venturi A, Giochetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999 13: 1103 8.
107. Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000 45: 1462 4.
108. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces bourladii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003 15: 697 8.
109. Ishikawa H, Akedo I, Umesaki Y, et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003 22: 56 63.
110. Mallon P, Mckay D, Kirk S, et al. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007 17: CD005573.
111. Summers RW, Elliott DE, Urban JF Jr., et al. Trichuris suis therapy in Crohn's disease. Gut 2005 54: 87 90.
112. Summers RW, Elliott DE, Urban JF Jr., et al. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 2005 128: 825 32.
113. Beck PL, Podolsky DK. Growth factors in inflammatory bowel disease. Inflamm Bowel Dis 1999 5: 44 60.
114. Dieckgraefe BK, Korzenik JR, Anant S. Growth factors as treatment options for intestinal inflammation. Ann NY Acad Sci 2006 1072: 300 6.
115. Sinha A, Nightingale JMD, West KP, et al. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003 349: 350 7.
116. Sandborn WJ, Sands BE, Wolf DC, et al. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double blind, placebo-controlled, dose escalation trial. Aliment Pharmacol Ther 2003 17: 1355 64.
117. Fabia R, Ar'Rajab A, Willen R, et al. Effects of phosphatidylcholine and phosphatidylinositol on acetic-acid-induced colitis in the rat. Digestion 1992 53: 35 44.
118. Mourelle M, Guarner F, Malagelada JR. Polyunsaturated phosphatidylcholine prevents stricture formation in a rat model of colitis. Gastroenterology 1996 110: 1093 7.
119. Stremmel W, Merle U, Zahn A, et al. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut 2005 54: 966 71.
120. Stremmel W, Ehehalt R, Autschbach F, et al. Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial. Ann Intern Med 2007 147: 603 10.
121. Stremmel W, Braun A, Hanermann A, et al. Retarded release phosphatidylcholine in non-steroid-treated ulcerative pancolitis: a randomised, controlled dose finding study. Gastroenterology 2008 134: 102 [#706].